Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 105.9%, from $237.00M to -$14.00M.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $103.25M | $103.25M | $103.25M | $103.25M | $0.00 | $0.00 | $0.00 | $246.00M | $622.00M | $0.00 | $0.00 | $66.00M | $237.00M | $0.00 | $3.08B | $0.00 | -$14.00M |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | +152.8% | -100.0% | — | — | +259.1% | -100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | +138.3% | — | — | — | -73.2% | -61.9% | — | — | -100.0% | -105.9% |